The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care 

Nov 16 2024
Marriott Marquis: Marriott - Grand Ballroom 125
7:30 PM - 9:30 PM

World Class Speakers

Naim Alkhouri
Industry Presenter

Naim Alkhouri

Arizona Liver Health
Amreen Dinani, MD FRCPC
Industry Presenter

Amreen Dinani, MD FRCPC

Duke University School of Medicine
Nicholas J Pennings, DO
Industry Presenter

Nicholas J Pennings, DO

Campbell University School Of Osteopathic Medicine

Description

This symposium will provide practical, interactive discussions of cardiometabolic pathophysiologic pathways, early identification and risk stratification, advances in treatment monitoring for disease progression, and long-term medical management, including the role of incretin agonists. 

Supported by: This activity is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals and Novo Nordisk, Inc. 
Organizer: Medtelligence

For more information and to register, visit: http://www.ReachMD.com/segment/26613

Objectives

  • Summarize the pathophysiologic rationale for using obesity pharmacotherapy in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH)
  • Apply recommendations for the treatment of patients with MASLD/MASH with GLP-1 RAs
  • Devise a multidisciplinary plan to manage obesity in patients with MASLD/MASH
  • Interpret data from clinical trials of emerging liver-directed therapies for MASLD/MASH
  • Interpret data from clinical trials of emerging anti-obesity therapies for MASLD/MASH